Omics sciences for systems biology in Alzheimer's disease: State-of-the-art of the evidence
| Autor: | Pedro L. Valenzuela, Alejandro Lucia, Harald Hampel, Massimo Corbo, Mark Mapstone, Nicholas T. Seyfried, Giulia Maria Sancesario, Pablo Lemercier, Enzo Emanuele, Francesco Garaci, Andrea Urbani, Simone Lista, George Perry, Filippo Baldacci, Nicola Toschi, Erica Modeste, Allan I. Levey, Andrea Vergallo, Robert Nisticò |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Aging Systems biology Alzheimer's disease Biomarker signatures Multiple omics Pathophysiology Precision medicine Genomics Humans Metabolomics Precision Medicine Alzheimer Disease Systems Biology Computational biology Biology Proteomics Fisiología humana Biochemistry 03 medical and health sciences 0302 clinical medicine Molecular Biology Epigenomics Biología molecular Enfermedad de alzheimer Settore BIO/14 Omics Biología de sistemas 030104 developmental biology Proteostasis Biomarcadores Neurology Alzheimer’s disease 030217 neurology & neurosurgery Biological network Biotechnology |
| Popis: | Alzheimer's disease (AD) is characterized by non-linear, genetic-driven pathophysiological dynamics with high heterogeneity in biological alterations and disease spatial-temporal progression. Human in-vivo and post-mortem studies point out a failure of multi-level biological networks underlying AD pathophysiology, including proteostasis (amyloid-β and tau), synaptic homeostasis, inflammatory and immune responses, lipid and energy metabolism, oxidative stress. Therefore, a holistic, systems-level approach is needed to fully capture AD multi-faceted pathophysiology. Omics sciences - genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics - embedded in the systems biology (SB) theoretical and computational framework can generate explainable readouts describing the entire biological continuum of a disease. Such path in Neurology is encouraged by the promising results of omics sciences and SB approaches in Oncology, where stage-driven pathway-based therapies have been developed in line with the precision medicine paradigm. Multi-omics data integrated in SB network approaches will help detect and chart AD upstream pathomechanistic alterations and downstream molecular effects occurring in preclinical stages. Finally, integrating omics and neuroimaging data - i.e., neuroimaging-omics - will identify multi-dimensional biological signatures essential to track the clinical-biological trajectories, at the subpopulation or even individual level. Sin financiación 10.895 JCR (2021) Q1, 25/195 Cell Biology 3.523 SJR (2021) Q1, 1/35 Aging No data IDR 2021 UEM |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|